chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient passed out almost 5 minutes after receiving the vaccine. I arrived about after hearing her father calling out for us to come help her. Her pulse was weak and we could not get a response from her. Her eyes had rolled back and after a few attempts followed with unresponsiveness we called 911. She did not seem to be in distress for air. She woke before the paramedics arrived. They checked her vitals and after she stabilized she declined to be taken to the hospital.
Received the first dose of the J&J vaccine as first dose,received a booster dose of Moderna; This spontaneous case was reported by a consumer and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (Received the first dose of the J&J vaccine as first dose,received a booster dose of Moderna) in a 64-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012F211A) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Oct-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 ml. On 22-Oct-2021, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Received the first dose of the J&J vaccine as first dose,received a booster dose of Moderna). On 22-Oct-2021, INTERCHANGE OF VACCINE PRODUCTS (Received the first dose of the J&J vaccine as first dose,received a booster dose of Moderna) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant medications were provided by the reporter. No Treatment information was reported. Patient received the first dose of the J&J vaccine as first dose, Lot: 1805029, received on 13March2021.
20hr following routine 6mo vax pt had high fever subjectively x several hr w/>1/2 hr crying;24hrs p/vax pt w/t99.3
Patient experienced light-headedness, pain in arm, being "off-balance," flashes of heat, wobbliness, tunnel vision, and being in a "fog" over the course of 72 hours. EMS services were called on behalf of the patient while she was at work, but based on my conversation with her, no action was taken at that time other than the patient leaving work to go home. Adverse effects resolved on their own after 72 hours.
This spontaneous report was received from a nurse and refers to an unspecified patient of unknown age and gender. There was no information regarding the patient's pertinent medical history, drug reactions, allergies or concomitant therapies provided. On 25-JAN-2017, the patient was vaccinated with improperly stored dose of VARIVAX lot # M005974, expiration date 02-FEB-2018 (site, dose and route of administration were not reported). The reason of the call was temperature alarm received via Digital Data Logger. It was reported that the vaccine were exposed to temperature of -14.4 Celsius degrees for 54 minutes before administration. No previous temperature excursion was reported. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information is not expected because all information was obtained.; Sender's Comments:  US-009507513-1611USA004113:
Client awoke at 5:30 AM 3/19/10 c/o pain (L) arm. Mom states (L) arm double in size. Mom gave child TYLENOL which has continued to give her q 6 hours and used cool compress to arm. At 11 AM noticed redness upper arm size of baseball.
All the vaccine leaked out; Leaked into the patient's arm; Leaked into the patient's arm; 1st dose on 03Aug2022, 2nd on 02Mar2023; This non-serious case was reported by a other health professional via call center representative and described the occurrence of accidental underdose in a 51-year-old male patient who received Herpes zoster (Shingrix) (batch number DP2x9, expiry date 05-OCT-2023) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on 3rd August 2022 intramuscularly).   On 02-MAR-2023, the patient received the 2nd dose of Shingrix (intramuscular, left arm). On 02-MAR-2023, an unknown time after receiving Shingrix, the patient experienced accidental underdose (Verbatim: All the vaccine leaked out), exposure via skin contact (Verbatim: Leaked into the patient's arm), inadvertent exposure to vaccine (Verbatim: Leaked into the patient's arm) and drug dose administration interval too long (Verbatim: 1st dose on 03Aug2022, 2nd on 02Mar2023). The outcome of the accidental underdose, exposure via skin contact, inadvertent exposure to vaccine and drug dose administration interval too long were unknown.   Additional Information: GSK Receipt date: 06-Mar-2023 A medical assistant from a clinic. She states that when giving a patient their second Shingrix vaccine on day of reporting, all the vaccine did not go into the patient's arm but leaked out and down the patient's arm.   She also reports that the patient got his first Shingrix vaccine which was past the 2 to 6 month recommended dosing schedule. Did not consent to follow-up.
A pre-diluted grey-top Pfizer covid vaccine vial (adult) was diluted with 1.8 mL of normal saline. Subsequently, an over-diluted 0.3 mL vaccine was administered to the patient for their booster. The patient was notified of this and the CDC recommendation that they are to repeat the dose immediately. He was able to return to the clinic the same day and receive the correct dose. No adverse events or clinical consequences were reported.
No additional AE information provided; product was not stored at 36F-46F after reconstitution and was held in the HCP's hand for up to 65 minutes before being administered to the patient; VARIVAX was administered to a patient approximately sixty-five minutes after product was reconstituted; This spontaneous report has been received from a registered nurse, regarding a patient of unknown age and gender. The patient's pertinent medical history, previous drug reactions or allergies, and concomitant medications were not reported.  On 14-OCT-2022, the patient was vaccinated with a dose of varicella virus vaccine live (Oka/Merck) (VARIVAX) subcutaneous injection (lot number: W017551, which was determined to be valid, with an expiration date on 01-JUN-2024) and an improperly storage dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) (albumin status rHA) Subcutaneous Injection (lot number: W009106, which was determined to be valid, with an expiration date on 04-DEC-2023), both as prophylaxis (strengths, doses, schemes, routes and anatomical locations of administration were not reported).  The reporter stated that the dose of varicella virus vaccine live (Oka/Merck) (VARIVAX) was administered to the patient approximately sixty-five minutes after product was reconstituted (Wrong technique in product usage process). And the administered dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) was not stored at 36 to 46 degrees Fahrenheit (F) after reconstitution and was held in the HCP's hand for up to 65 minutes before being administered to the patient (Product storage error). No additional adverse event was reported.
STOMACH PAIN AND VOMITING ON 4/15/21. POST VOMITING STOMACH FELT BETTER CHILLS AND WEAKNESS DAY AFTER VACCINE. RECOMMENDED TYLENOL/IBUPROFEN FOR PAIN OR FEVER AND HYDRATION.
No AE; VARIVAX LOT T010314, expiration date 3/24/2022 was accidentally administered to a patient on April 11, 2022.; This spontaneous report was received from an office manager on behalf of health care office, referring to a patient of unspecified age and gender. The patient's medical history, concurrent conditions, concomitant therapies, and previous drug reactions or allergies were not reported.  On 11-APR-2022, the patient was accidentally vaccinated with an expired dose of varicella virus vaccine live (Oka/Merck) (VARIVAX) 0.5 milliliters, as prophylaxis (route of administration, vaccine scheme, and anatomical site of vaccination were not reported; lot number T010314 has been verified to be valid, expiration date reported and established as 24-MAR-2022) (expired product administered).   It was reported that the product was stored appropriately, and it did not have any temperature excursions. No additional adverse event was reported (no adverse event).
patient was administered an expired dose of Kinrix; This non-serious case was reported by a nurse via call center representative and described the occurrence of expired vaccine used in a 4-year-old female patient who received DTPa-IPV (Kinrix) (batch number PX27D, expiry date 17-JAN-2023) for prophylaxis.   On 01-AUG-2023, the patient received Kinrix. On 01-AUG-2023, an unknown time after receiving Kinrix, the patient experienced expired vaccine used (Verbatim: patient was administered an expired dose of Kinrix). The outcome of the expired vaccine used was unknown.   This report is made without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: Receipt Date: 02-AUG-2023 The Vaccine Administration Facility was the same as Primary Reporter. The reporter consented to follow up. The patient was administered an expired dose of Kinrix, which led to expired vaccine used.
only exercise for 15 minutes and he has to go to bed and rest; Terrible pain; slight dizziness; feet felt heavy; muscle collapse; threw out his knee; Discomfort; This case was reported by a consumer via call center representative and described the occurrence of muscle disorder in a adult male patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included sinus operation. Previously administered products included Shingrix with an associated reaction of discomfort (received 1st dose on an unknown date and experienced discomfort).   On 7th August 2019, the patient received the 2nd dose of Shingrix. In August 2019, 6 days after receiving Shingrix, the patient experienced muscle disorder, knee pain and discomfort. On an unknown date, the patient experienced energy decreased, pain, dizziness and heaviness in extremities. Rechallenge with Shingrix was positive. On an unknown date, the outcome of the muscle disorder, knee pain, energy decreased, dizziness and heaviness in extremities were unknown and the outcome of the discomfort and pain were recovered/resolved.   It was unknown if the reporter considered the muscle disorder, knee pain, discomfort, energy decreased, pain, dizziness and heaviness in extremities to be related to Shingrix.  Additional details were received as follows: The age at vaccination was not reported. The patient received his second dose and experienced muscle collapse and he threw out his knee. The patient also experienced mild discomfort for about 3 days. The patient gone to 6 doctors and all of his blood tests come back as normal. The patient was very healthy and used to work out 5 days per week and go dancing regularly. After vaccination patient can only exercise for 15 minutes and he has to go to bed and rest. For 1 month he was in terrible pain, but it had passed. The patient began a mild exercise routine for 4 weeks, but developed slight dizziness and his feet felt heavy.      Lab Comments: On an unknown date blood test was done
got very sick; received two vaccines; This spontaneous report was received from a lawyer and refers to a currently 69-year-old female patient. Her concurrent conditions included unspecified rheumatic disorder, chiropractic, anxiety, bursitis of hips, back pain and arthritis. She did not smoke or use tobacco. The patient's medical history included uterine cancer treated with hysterectomy and shingles. The patient's concomitant therapies included alprazolam. Her historical vaccines included unspecified flu vaccines and zoster vaccine live (ZOSTAVAX).   On an unknown date in 2018, the patient was vaccinated with two doses of unspecified pneumococcal vaccine (manufacturer unknown) (dose, route of administration, anatomical location, lot # and expiry date were not provided) for prophylaxis. She stated that one of the vaccines might not have been pneumonia vaccine. On an unknown date, the patient got very sick due to vaccinations. The outcome of the event was not reported.  The reporter considered the event to be related to pneumococcal vaccine (manufacturer unknown).  This is one of two reports concerning the same patient.; Sender's Comments:  US-009507513-1805USA005951:
No adverse effect reported; patient was admnistered improperly stored doses of PROQUAD; Information has been received from a nurse referring to a 5 years old patient of unknown gender.There was no information about the patient's concurrent conditions, concomitant therapies or medical histories provided.   On 21-MAR-2019, the patient were vaccinated with improperly stored stored doses of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) lot number R020676, expiration date 15-JAN-2020 (dose and route of administration were not reported). The sterile diluent, lot number S003325, expiration date 03-NOV-2019, was properly stored. There was no adverse effect reported. Administered doses of vaccines experienced the temperature excursion of 6 to 14 (10.4) Fahrenheit for 18 minutes. Data logger was involved. There were no previous excursions reported.  This is one of two reports received from the same reporter.; Sender's Comments:  US-009507513-1904USA001029:
Systemic: Allergic: Itch (specify: facial area, extremeties)-Mild, Additional Details: PT says that they got a rash all over the hands a day after getting the covid-19 vaccine, Has gone away but made his skin itchy and flaky since.
Sudden death  (Patient's son should have access to COVID-19 vaccination card with lot numbers and location where vaccine was administered.)
Information has been received from a nurse practi concerning a 17 year old female who on 19-MAY-2008 was vaccinated IM with a 0.5 ml first dose of GARDASIL (lot# 655604/0052X). On 20-MAY-2008 the patient experienced nausea, vomiting, diarrhea and "pin point" rash on her face. Unknown medical attention was sought by calling the practice. At the time of reporting the patient had not recovered from nausea, vomiting, diarrhea and pin point rash on her face. Additional information has been requested.
Patient became extremely diaphoretic with a syncopal episode.  Patient was lethargic and unable to answer questions approximately 5 after occurrence of episode.
ASSESSMENT/PLAN: Acute issues: Spinal stenosis with significant weakness POA - s/p op, (8/20), C3-5 discectomy with decompression and fusion, please see op note. Patient doing well, continue s/p op per neurosurgery service, aspirin on hold advance per neurosurgery (Hold aspirin x 3 months post op as this inhibits bone fusion. S/p Neck exploration for possible prevertebral hematoma and dysphagia on 8/26. Per Neurosurgery on 8/30/21   COVID 19 was + 8/20 - projected time of removal of isolation is 8/31.  INCIDENTAL FINDING.  ASYMPTOMATIC
Fever. Shingles. Urgent Care. Antiviral drug. Pain med. Still have shingles almost a month later. Back pain, stomach pain, itch.
Pregnant; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of EXPOSURE DURING PREGNANCY (Pregnant) in a 35-year-old female patient (gravida 1, para 0) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011J20A and 041LZ0A) for COVID-19 vaccination.     The patient's past medical history included Alcohol use (2 drinks a week) on 21-Aug-2020. Concurrent medical conditions included Drug allergy (Sulfa drugs was reported.). Concomitant products included PRENATAL VITAMINS [ASCORBIC ACID;BETACAROTENE;CALCIUM SULFATE;COLECALCIFEROL;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL ACETATE;RIBOFLAVIN;THIAMINE MONONITRATE;TOCOPHERYL ACETATE;ZINC OXIDE] for an unknown indication.   On 29-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. The patient's last menstrual period was on 21-Aug-2020 and the estimated date of delivery was 24-May-2021. On an unknown date, the patient experienced EXPOSURE DURING PREGNANCY (Pregnant). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  eighteenth week of the pregnancy.  At the time of the report, EXPOSURE DURING PREGNANCY (Pregnant) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, Blood glucose: normal (normal) normal. In 2021, Ultrasound abdomen: normal (normal) normal.         No treatment information was provided. Previous pregnancies were not present.
swelling at injection site; pain at injection site; This case was reported by a consumer via call center representative and described the occurrence of injection site swelling in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, unknown after receiving Shingrix, the patient experienced injection site swelling and injection site pain. On an unknown date, the outcome of the injection site swelling and injection site pain were unknown.   It was unknown if the reporter considered the injection site swelling and injection site pain to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. No further details were available. The follow up consent was not granted.
Post vax, the pt developed an injection site reaction that included redness, tenderness, swelling, and hot to the touch. No fever was noted. The physician was concerned that the pt had cellulitis, but after icing and Benadryl his condition improved.
my elbow is hurting to joint; This is a spontaneous report from a contactable consumer or other non-health care professional (patient). A patient of unspecified age and gender received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation : solution for injection, Batch/Lot Number: Unknown, expiry date : not reported ), via an unspecified route of administration on an unspecified date in May2021 as DOSE 2, SINGLE for covid-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported.The patient previously took first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation : solution for injection, Batch/Lot Number: Unknown, expiry date : not reported) via an unspecified route of administration on 07Apr2021 as DOSE 1, SINGLE for covid-19 immunisation. On an unspecified date, the patient experienced elbow was hurting to joint. The outcome of the event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Syncope/fall  s/p vaccine #1, abrasion under chin>ED>dc'd declined txt
3 days later, she noticed that On the left neck side, there are 3 nodules that are big and still there; 3 days later, she noticed that On the left neck side, there are 3 nodules that are big and still there; Next day morning, she had nodes in her under arm; Under her left arm, there was a node that was painful; This spontaneous case was reported by a consumer and describes the occurrence of LYMPH NODE PAIN (Next day morning, she had nodes in her under arm), LYMPH NODE PAIN (Under her left arm, there was a node that was painful), LYMPHADENOPATHY (3 days later, she noticed that On the left neck side, there are 3 nodules that are big and still there) and LYMPH NODE PAIN (3 days later, she noticed that On the left neck side, there are 3 nodules that are big and still there) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included ERGOCALCIFEROL, RETINOL PALMITATE (VITAMINS A & D) for an unknown indication.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Mar-2021, the patient experienced LYMPH NODE PAIN (Under her left arm, there was a node that was painful). On 27-Mar-2021, the patient experienced LYMPHADENOPATHY (3 days later, she noticed that On the left neck side, there are 3 nodules that are big and still there). On an unknown date, the patient experienced LYMPH NODE PAIN (Next day morning, she had nodes in her under arm) and LYMPH NODE PAIN (3 days later, she noticed that On the left neck side, there are 3 nodules that are big and still there). At the time of the report, LYMPH NODE PAIN (Under her left arm, there was a node that was painful) and LYMPHADENOPATHY (3 days later, she noticed that On the left neck side, there are 3 nodules that are big and still there) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
p/vax pt had a small sx lasting about 40seconds;mom states pt also had a sz @ 6mo of age;no other sz until today;advised to take pt to MD for eval;
This spontaneous report received from a registered nurse refers to a 4 year old male patient with no illness at time of vaccination. The patient's historical condition include asthma and eczema. Historical vaccines were not reported.Concomitant therapies included hydroxyzine and cetirizine hydrochloride( (ZYRTEC). On 18-SEP-2018, the patient was vaccinated with the second an improperly stored second dose of M-M-R II, subcutaneous in the left thigh, lot # R011802 (expiration date was not provided) and with an improperly stored fourth dose (also reported as 4/3) of QUADRACEL lot # C5325BA (expiration date was not provided), intramuscularly (IM) in the left thigh. Both vaccines were administered for prophylaxis and purchased with public funds. None patient experience was reported. The administered doses of the vaccines experienced a freezer temperature excursion (not specified) (product storage error) as recorded from a digital data logger which ocurred at the time of storage in clinical practice. No adverse effect was reported. Lot number R011802 is an invalid lot number for M-M-R II. This is one of several reports received from the same reporter.; Sender's Comments: US-009507513-1809USA010598: US-009507513-1901USA002753: US-009507513-1901USA002754: US-009507513-1901USA002755: US-009507513-1901USA002756: US-009507513-1901USA002757: US-009507513-1901USA002758: US-009507513-1901USA002759: US-009507513-1901USA002760: US-009507513-1901USA002761: US-009507513-1901USA002762: US-009507513-1901USA002763: US-009507513-1901USA002765:
Tachycardia since 11/8/2021 and feeling winded with any physical movement. Unable to exercise after 1 month.